Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: A joint study by the European Association of Urology-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration

A Necchi, S Lo Vullo, L Mariani, M Moschini, K Hendricksen, M Rink, R Sosnowski, J Dobruch, JD Raman, CG Wood, V Margulis, M Roupret, A Briganti, F Montorsi, E Xylinas, SF Shariat, on behalf of the European Association of Urology–Young Academic Urologists (EAU–YAU), Urothelial Cancer Group and the Upper Tract Urothelial Carcinoma Collaboration group

Research output: Contribution to journalArticle

Abstract

Objective: To analyse the outcomes of adjuvant chemotherapy vs observation in a multicentre cohort of patients with upper tract urothelial carcinoma (UTUC) in order to clarify whether such patients benefit from adjuvant chemotherapy after radical nephroureterectomy (RNU). Patients and Methods: Data from 15 centres were collected for a total of 1544 patients, treated between 2000 and 2015. Criteria for patient selection included pT2-4N0/x stage, or lymph node-positive disease, and prior RNU. The standardized difference approach was used to compare subgroup characteristics. Overall survival (OS) was the primary endpoint. The primary analysis used 1:1 propensity score matching, with inverse probability of treatment weighting in addition to this in the secondary analysis. The latter was also performed with the inclusion of covariates, i.e. with 'doubly robust' estimation. A 6-month landmark analysis was performed to exclude early events. Results: A total of 312 patients received adjuvant chemotherapy and 1232 underwent observation. Despite differences between the two groups, the standardized difference was generally <10% after matching. In the matched analysis no difference was observed in OS between adjuvant chemotherapy and observation (hazard ratio [HR] 1.14, 95% confidence inverval [CI] 0.91-1.43; P = 0.268). In the doubly robust estimate-adjusted comparison, adjuvant chemotherapy was significantly associated with shorter OS (HR 1.26, 95% CI 1.02-1.54; P = 0.032). Similar findings were confirmed in subgroup analyses stratified by pathological stage, and after landmark analysis. Results should be interpreted with consideration given to the inherent limitations of retrospective studies. Conclusion: Adjuvant chemotherapy did not improve OS compared with observation in the present study. These results contribute to the uncertainties regarding postoperative chemotherapy in UTUC, and suggest dedicated prospective trials, new more potent therapies, and the identification of enhanced patient selection criteria are required. © 2017 BJU International.
Original languageEnglish
Pages (from-to)252-259
Number of pages8
JournalBJU International
Volume121
Issue number2
DOIs
Publication statusPublished - 2018

Fingerprint

Adjuvant Chemotherapy
Carcinoma
Survival
Observation
Patient Selection
Propensity Score
Uncertainty
Urologists
Retrospective Studies
Lymph Nodes
Drug Therapy
Therapeutics

Cite this

Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: A joint study by the European Association of Urology-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration. / Necchi, A; Lo Vullo, S; Mariani, L; Moschini, M; Hendricksen, K; Rink, M; Sosnowski, R; Dobruch, J; Raman, JD; Wood, CG; Margulis, V; Roupret, M; Briganti, A; Montorsi, F; Xylinas, E; Shariat, SF; group, on behalf of the European Association of Urology–Young Academic Urologists (EAU–YAU), Urothelial Cancer Group and the Upper Tract Urothelial Carcinoma Collaboration .

In: BJU International, Vol. 121, No. 2, 2018, p. 252-259.

Research output: Contribution to journalArticle

Necchi, A, Lo Vullo, S, Mariani, L, Moschini, M, Hendricksen, K, Rink, M, Sosnowski, R, Dobruch, J, Raman, JD, Wood, CG, Margulis, V, Roupret, M, Briganti, A, Montorsi, F, Xylinas, E, Shariat, SF & group, OBOTEAOUYAUEAUYAUUCGATUTUCC 2018, 'Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: A joint study by the European Association of Urology-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration', BJU International, vol. 121, no. 2, pp. 252-259. https://doi.org/10.1111/bju.14020
Necchi, A ; Lo Vullo, S ; Mariani, L ; Moschini, M ; Hendricksen, K ; Rink, M ; Sosnowski, R ; Dobruch, J ; Raman, JD ; Wood, CG ; Margulis, V ; Roupret, M ; Briganti, A ; Montorsi, F ; Xylinas, E ; Shariat, SF ; group, on behalf of the European Association of Urology–Young Academic Urologists (EAU–YAU), Urothelial Cancer Group and the Upper Tract Urothelial Carcinoma Collaboration . / Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: A joint study by the European Association of Urology-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration. In: BJU International. 2018 ; Vol. 121, No. 2. pp. 252-259.
@article{146ced9a3f054350877ff77d826f623b,
title = "Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: A joint study by the European Association of Urology-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration",
abstract = "Objective: To analyse the outcomes of adjuvant chemotherapy vs observation in a multicentre cohort of patients with upper tract urothelial carcinoma (UTUC) in order to clarify whether such patients benefit from adjuvant chemotherapy after radical nephroureterectomy (RNU). Patients and Methods: Data from 15 centres were collected for a total of 1544 patients, treated between 2000 and 2015. Criteria for patient selection included pT2-4N0/x stage, or lymph node-positive disease, and prior RNU. The standardized difference approach was used to compare subgroup characteristics. Overall survival (OS) was the primary endpoint. The primary analysis used 1:1 propensity score matching, with inverse probability of treatment weighting in addition to this in the secondary analysis. The latter was also performed with the inclusion of covariates, i.e. with 'doubly robust' estimation. A 6-month landmark analysis was performed to exclude early events. Results: A total of 312 patients received adjuvant chemotherapy and 1232 underwent observation. Despite differences between the two groups, the standardized difference was generally <10{\%} after matching. In the matched analysis no difference was observed in OS between adjuvant chemotherapy and observation (hazard ratio [HR] 1.14, 95{\%} confidence inverval [CI] 0.91-1.43; P = 0.268). In the doubly robust estimate-adjusted comparison, adjuvant chemotherapy was significantly associated with shorter OS (HR 1.26, 95{\%} CI 1.02-1.54; P = 0.032). Similar findings were confirmed in subgroup analyses stratified by pathological stage, and after landmark analysis. Results should be interpreted with consideration given to the inherent limitations of retrospective studies. Conclusion: Adjuvant chemotherapy did not improve OS compared with observation in the present study. These results contribute to the uncertainties regarding postoperative chemotherapy in UTUC, and suggest dedicated prospective trials, new more potent therapies, and the identification of enhanced patient selection criteria are required. {\circledC} 2017 BJU International.",
author = "A Necchi and {Lo Vullo}, S and L Mariani and M Moschini and K Hendricksen and M Rink and R Sosnowski and J Dobruch and JD Raman and CG Wood and V Margulis and M Roupret and A Briganti and F Montorsi and E Xylinas and SF Shariat and group, {on behalf of the European Association of Urology–Young Academic Urologists (EAU–YAU), Urothelial Cancer Group and the Upper Tract Urothelial Carcinoma Collaboration}",
year = "2018",
doi = "10.1111/bju.14020",
language = "English",
volume = "121",
pages = "252--259",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "2",

}

TY - JOUR

T1 - Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: A joint study by the European Association of Urology-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration

AU - Necchi, A

AU - Lo Vullo, S

AU - Mariani, L

AU - Moschini, M

AU - Hendricksen, K

AU - Rink, M

AU - Sosnowski, R

AU - Dobruch, J

AU - Raman, JD

AU - Wood, CG

AU - Margulis, V

AU - Roupret, M

AU - Briganti, A

AU - Montorsi, F

AU - Xylinas, E

AU - Shariat, SF

AU - group, on behalf of the European Association of Urology–Young Academic Urologists (EAU–YAU), Urothelial Cancer Group and the Upper Tract Urothelial Carcinoma Collaboration

PY - 2018

Y1 - 2018

N2 - Objective: To analyse the outcomes of adjuvant chemotherapy vs observation in a multicentre cohort of patients with upper tract urothelial carcinoma (UTUC) in order to clarify whether such patients benefit from adjuvant chemotherapy after radical nephroureterectomy (RNU). Patients and Methods: Data from 15 centres were collected for a total of 1544 patients, treated between 2000 and 2015. Criteria for patient selection included pT2-4N0/x stage, or lymph node-positive disease, and prior RNU. The standardized difference approach was used to compare subgroup characteristics. Overall survival (OS) was the primary endpoint. The primary analysis used 1:1 propensity score matching, with inverse probability of treatment weighting in addition to this in the secondary analysis. The latter was also performed with the inclusion of covariates, i.e. with 'doubly robust' estimation. A 6-month landmark analysis was performed to exclude early events. Results: A total of 312 patients received adjuvant chemotherapy and 1232 underwent observation. Despite differences between the two groups, the standardized difference was generally <10% after matching. In the matched analysis no difference was observed in OS between adjuvant chemotherapy and observation (hazard ratio [HR] 1.14, 95% confidence inverval [CI] 0.91-1.43; P = 0.268). In the doubly robust estimate-adjusted comparison, adjuvant chemotherapy was significantly associated with shorter OS (HR 1.26, 95% CI 1.02-1.54; P = 0.032). Similar findings were confirmed in subgroup analyses stratified by pathological stage, and after landmark analysis. Results should be interpreted with consideration given to the inherent limitations of retrospective studies. Conclusion: Adjuvant chemotherapy did not improve OS compared with observation in the present study. These results contribute to the uncertainties regarding postoperative chemotherapy in UTUC, and suggest dedicated prospective trials, new more potent therapies, and the identification of enhanced patient selection criteria are required. © 2017 BJU International.

AB - Objective: To analyse the outcomes of adjuvant chemotherapy vs observation in a multicentre cohort of patients with upper tract urothelial carcinoma (UTUC) in order to clarify whether such patients benefit from adjuvant chemotherapy after radical nephroureterectomy (RNU). Patients and Methods: Data from 15 centres were collected for a total of 1544 patients, treated between 2000 and 2015. Criteria for patient selection included pT2-4N0/x stage, or lymph node-positive disease, and prior RNU. The standardized difference approach was used to compare subgroup characteristics. Overall survival (OS) was the primary endpoint. The primary analysis used 1:1 propensity score matching, with inverse probability of treatment weighting in addition to this in the secondary analysis. The latter was also performed with the inclusion of covariates, i.e. with 'doubly robust' estimation. A 6-month landmark analysis was performed to exclude early events. Results: A total of 312 patients received adjuvant chemotherapy and 1232 underwent observation. Despite differences between the two groups, the standardized difference was generally <10% after matching. In the matched analysis no difference was observed in OS between adjuvant chemotherapy and observation (hazard ratio [HR] 1.14, 95% confidence inverval [CI] 0.91-1.43; P = 0.268). In the doubly robust estimate-adjusted comparison, adjuvant chemotherapy was significantly associated with shorter OS (HR 1.26, 95% CI 1.02-1.54; P = 0.032). Similar findings were confirmed in subgroup analyses stratified by pathological stage, and after landmark analysis. Results should be interpreted with consideration given to the inherent limitations of retrospective studies. Conclusion: Adjuvant chemotherapy did not improve OS compared with observation in the present study. These results contribute to the uncertainties regarding postoperative chemotherapy in UTUC, and suggest dedicated prospective trials, new more potent therapies, and the identification of enhanced patient selection criteria are required. © 2017 BJU International.

U2 - 10.1111/bju.14020

DO - 10.1111/bju.14020

M3 - Article

VL - 121

SP - 252

EP - 259

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 2

ER -